Related Experiment Videos
Aggressive chemotherapy for acute leukemia relapsed after transplantation
S Sica1, P Salutari, A Di Mario
1Istituto di Semeiotica Medica, Universitá Cattolica del Sacro Cuore Roma, Italia.
Leukemia & Lymphoma
|September 1, 1994
Summary
Relapse after bone marrow transplantation (BMT) for leukemia remains a challenge. Late relapses after BMT show better response to chemotherapy, offering potential for long-term survival in select patients.
Area of Science:
- Hematology
- Oncology
- Transplantation Medicine
Background:
- Bone marrow transplantation (BMT) is a key treatment for hematological malignancies.
- Leukemia recurrence post-BMT is a primary cause of treatment failure.
- Standardized treatments for relapsed leukemia after BMT are lacking.
Purpose of the Study:
- To evaluate treatment strategies for patients with relapsed leukemia after autologous or allogeneic BMT.
- To differentiate outcomes based on the timing of relapse (early vs. late).
Main Methods:
- Retrospective analysis of 13 patients (7 ANLL, 6 ALL) treated for relapse post-BMT.
- Categorization of patients based on relapse timing: <9 months (early) and >9 months (late).
- Assessment of treatment response and survival duration.
Main Results:
- Early relapsed patients (n=6) showed no response and had a median survival of 5.5 months.
- Late relapsed patients (n=7) demonstrated a high response rate (5 CR, 1 PR) with intensive chemotherapy.
- Late relapses achieved a longer median survival of 14 months.
Conclusions:
- Late relapse after BMT may benefit from intensive chemotherapy, offering improved survival.
- Careful patient selection is crucial for chemotherapy post-BMT to achieve long-term disease-free survival.
- Further research into optimized post-BMT relapse strategies is warranted.